ElucidVivo A.3 vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

ElucidVivo A.3

by Elucid Bioimaging

EchoNext

by Pathway Labs

AI Verdict

ElucidVivo A.3 and EchoNext are adjacent competitors in cardiovascular AI, as both aim to improve cardiac care but focus on different diagnostic modalities and disease aspects. ElucidVivo A.3 analyzes CT angiography to quantify arterial plaque composition and stability for atherosclerosis patient stratification, while EchoNext analyzes standard ECGs to detect hidden structural heart disease like heart failure and valve disease. Therefore, the choice between them depends on whether the clinical need is for detailed plaque analysis from CT or broad structural heart disease screening from ECGs.

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you need detailed, quantitative analysis of arterial plaque composition and stability from CT angiography. This tool is ideal for stratifying patients with atherosclerosis and optimizing treatment decisions based on precise visualization and measurement of plaque characteristics, including Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, validated against histology.

View ElucidVivo A.3 →

Choose EchoNext if…

Choose EchoNext if you require an AI-powered screening tool to detect hidden structural heart disease from standard ECGs. This is particularly useful for identifying risks of heart failure, valve disease, and pulmonary hypertension early, even before symptoms present, and can help determine which patients should undergo further evaluation with an echocardiogram.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	ElucidVivo A.3	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR).	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools are FDA-cleared and designed for clinical use, implying a certain level of usability and integration into existing workflows. However, without specific details on user interface, training requirements, or integration complexities for either product beyond their deployment methods, it is difficult to definitively declare a winner. ElucidVivo A.3 integrates with PACS/EMR, while EchoNext is available through the OpenEvidence platform.

Clinical Value

Tie

Both tools offer significant clinical value by addressing critical areas in cardiovascular health. ElucidVivo A.3 provides detailed quantitative analysis of arterial plaque, aiding in atherosclerosis patient stratification and treatment optimization. EchoNext, on the other hand, detects hidden structural heart disease from standard ECGs, offering broad screening capabilities for conditions like heart failure and valve disease. The 'winner' depends on the specific clinical need being addressed.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and discounts, making its cost structure clear to potential buyers. ElucidVivo A.3's pricing is listed as 'contact for pricing,' which provides less immediate transparency for comparison. While the ultimate value depends on specific organizational needs and ROI, EchoNext's transparent pricing gives it an edge in this dimension.

Enterprise Readiness

EchoNext

EchoNext explicitly states its target size, ranging from major hospitals to community practices, and offers tiered pricing plans including 'Custom' for larger schools with 500+ students annually, implying scalability and enterprise-level considerations. It also details custom enhancements and integrations. While ElucidVivo A.3 is expected to integrate with PACS/EMR, EchoNext's explicit mention of various organizational sizes and custom plans suggests a more clearly articulated enterprise readiness strategy.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. ElucidVivo A.3's AI-powered quantitative analysis of arterial plaque composition, validated against histology, represents a novel approach to atherosclerosis assessment. EchoNext's ability to detect hidden structural heart disease from standard ECGs, a widely available diagnostic tool, also showcases innovative application of AI for early detection. Both are pushing the boundaries of AI in cardiology.

Support & Docs

Tie

Neither the provided structured facts nor general web searches offer explicit details regarding the level of customer support, documentation, or training resources available for either ElucidVivo A.3 or EchoNext. Without this information, it is not possible to differentiate between the two tools in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	ElucidVivo A.3	EchoNext
Name	ElucidVivo A.3	EchoNext
Company	Elucid Bioimaging	Pathway Labs
Description	FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring ElucidVivo A.3 and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

ElucidVivo A.3 is a software application that explicitly details DICOM integration and PACS/EMR interoperability, following typical clinical workflow patterns for image processing, review, and analysis. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, which aims to embed its screening output directly into tools physicians already use during patient visits, rather than requiring a separate workflow.

What is the accuracy and sensitivity of each tool in detecting relevant cardiac conditions?

ElucidVivo A.3 provides AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography, with its plaque characteristics validated against histology. It also derives fractional flow reserve (FFRct) with high accuracy compared to invasive FFR. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. In studies, EchoNext achieved a diagnostic accuracy of 77% for structural heart problems, outperforming cardiologists who had 64% accuracy without AI assistance and 69% with AI assistance.

What is the learning curve for physicians adopting each tool, and what kind of support is available?

ElucidVivo A.3's analysis involves intricate details that may suggest a steeper learning curve compared to more automated systems. While ElucidVivo A.3 integrates into workflows, specific details regarding its support channels or comprehensive public documentation are not explicitly outlined in available information. EchoNext is integrated into the OpenEvidence platform, which is used by many physicians, potentially simplifying adoption. Pathway Labs aims to get EchoNext into real workflows across health systems at a national scale.

What clinical context is most appropriate for each tool, and for which specialties are they best suited?

ElucidVivo A.3 is best suited for cardiologists, radiologists, and vascular surgeons who require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions. EchoNext is designed for broad access, from major hospitals to community practices, and is suitable for cardiologists, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to screen for hidden structural heart disease.

What are the considerations for a multi-site rollout of each tool, particularly regarding security and integration?

ElucidVivo A.3 explicitly details DICOM integration, PACS/EMR interoperability, and states 'SOC 2 / HIPAA-aligned data protection,' demonstrating a robust commitment to enterprise IT and security standards crucial for seamless integration into complex healthcare IT environments. EchoNext's partnership with OpenEvidence aims to place its screening output directly into a platform many physicians already use, facilitating broad access in both tertiary centers and community practices without requiring a separate system.